Skip to main content
. 2022 Jul 11;2022:7037497. doi: 10.1155/2022/7037497

Table 2.

Lymphocyte subsets and sPD-1 levels.

n WM group EA group t P
CD3 + T (%) 30 T0 58.06 ± 11.14 60.12 ± 11.22 0.713 0.479
T1 59.33 ± 10.42 60.89 ± 11.35 0.840 0.404
T2 61.04 ± 10.30 66.84 ± 8.75 2.351 0.022

CD4 + T (%) 30 T0 37.26 ± 11.10 37.07 ± 8.65 -0.022 0.983
T1 37.74 ± 9.49 38.32 ± 8.50 0.149 0.882
T2 39.50 ± 10.46 45.47 ± 7.78 2.176 0.034

NK cells (%) 30 T0 20.45 ± 9.95 20.13 ± 8.00 -0.137 0.892
T1 17.56 ± 7.50 18.29 ± 7.95 0.369 0.714
T2 16.93 ± 6.93 21.71 ± 8.06 2.463 0.017

sPD-1 (pg/mL) 30 T0 141.22 ± 41.05 142.77 ± 36.57 -0.155 0.877
T1 138.62 ± 38.86 134.23 ± 31.71 -0.466 0.643
T2 137.87 ± 41.90 116.28 ± 36.83 -2.119 0.038

CD3 + T: percentage of CD3 + T lymphocytes; CD4 + T: percentage of CD4 + T lymphocytes; NK cells: percentage of natural killer cells; sPD-1: level of programmed death factor in plasma; T0: before treatment; T1 and T2: three and five days after treatment, respectively. Data are presented as means ± SD or as median (IQR). Compared with the WM group, P < 0.05.